Pharmed Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review
- June 17, 2026
- Posted by: Kunal Singla
- Category: News
Pharmed (NSE:PHARMED) CMP: Rs 160 (2026). Sector: Pharmaceuticals and Healthcare. JM Financial: Neutral Rs 192. Kotak Securities: Neutral Rs 175. Consensus: Rs 184. Bull: Rs 192. Bear: Rs 156.
The Pharmed stock prediction for 2026 from leading brokerages covers a range reflecting sector dynamics, earnings trajectory and the macro environment. All estimates may or may not be achieved. Treat any Pharmed share price prediction as one data point and not as a guarantee of future performance.
This article reviews every dimension of the Pharmed stock forecast analysts are tracking, including key drivers, bull and bear scenarios and the primary risks. Verify all figures with the latest brokerage reports before any investment decision.
Click Here – Get Free Investment Predictions
What Analysts Predict for Pharmed Stock in 2026
Analyst consensus on the Pharmed stock prediction for 2026 is tracked by leading brokerages. The table below shows the latest available data from JM Financial and Kotak Securities. All figures are sourced from publicly available research and should be verified before publishing.
| Brokerage | Rating | Pharmed Stock Prediction (Rs) | Updated |
|---|---|---|---|
| JM Financial | Neutral | Rs 192 | 2026 |
| Kotak Securities | Neutral | Rs 175 | 2026 |
| Analyst Consensus | — | Rs 184 | 2026 |
The analyst target range for Pharmed reflects genuine difference of opinion on demand recovery, margin trajectory and sector headwinds. The implied upside in the Pharmed stock forecast from the current price of Rs 160 may or may not be realised by end of 2026.
3 Stocks Building Serious Momentum Right Now
When Univest analysts identify high-conviction stock opportunities, investors pay attention.
Our research team has shortlisted the Top Stocks to Buy based on current market momentum, sector trends & growth potential for 2026.
- Discover stocks investors are actively accumulating
- High-conviction opportunities backed by research
- Designed for the next phase of market growth
Unlock the latest Top Stock Picks now on Univest
Pharmed Company Overview
Pharmed Ltd is a significant player in India’s pharmaceutical industry with a presence across domestic formulations, US generics and specialty segments. The Pharmed stock prediction for 2026 reflects both the pipeline growth potential and regulatory risk.
| Metric | Value |
|---|---|
| NSE Ticker | PHARMED |
| Sector | Pharmaceuticals and Healthcare |
| CMP | Rs 160 (2026) |
| 52 Week High | — |
| 52 Week Low | — |
| Market Cap | — |
| P/E Ratio | — |
| Pharmed Stock Prediction Consensus (12M) | Rs 184 |
Pharmed Stock Prediction by Time Horizon
Analysts split the Pharmed share price prediction across time frames as near-term drivers differ materially from the long-term view.
Short-Term Pharmed Stock Prediction
The near-term Pharmed stock forecast reflects current sentiment, sector news and upcoming earnings prints. Key support and resistance levels around Rs 160 are being watched closely. A short-term Pharmed share price prediction carries the most uncertainty of any time horizon.
12-Month Pharmed Stock Prediction
JM Financial targets Rs 192 (Neutral) and Kotak Securities targets Rs 175 (Neutral). Most desks refresh their Pharmed stock forecast within two to four weeks of each quarterly earnings print. The Pharmed share price prediction should be verified against the most recent analyst reports.
Long-Term Pharmed Stock Prediction
The long-term outlook for Pharmed is built on assumptions about demand recovery, margin expansion and revenue diversification in the Pharmaceuticals and Healthcare sector. Long-term price targets carry the most uncertainty and should be treated as directional guidance only.
Pharmed Stock Forecast: Key Factors
The following four factors appear consistently in analyst research on Pharmed and are the primary inputs into the bull and bear case scenarios.
US Generic Revenue
US generics revenue is the most watched metric in the Pharmed stock forecast. USFDA approval timelines and price erosion rates directly affect the Pharmed share price prediction from most research desks.
Domestic Formulations Growth
Domestic formulation growth provides a stable base that supports the Pharmed stock prediction even when export growth faces headwinds.
R&D Pipeline
The depth and commercialization pace of the R&D pipeline is a key variable in the long-term Pharmed share price prediction. New product approvals are cited as catalysts for the Pharmed stock prediction.
EBITDA Margin
Sustained EBITDA margin expansion is typically the basis for the bullish Pharmed stock forecast. Margin recovery strengthens the Pharmed share price prediction from most research desks.
Pharmed Stock Prediction: Bull and Bear Scenarios
| Scenario | Pharmed Stock Prediction | Key Conditions |
|---|---|---|
| Bull Case | Rs 192 | Strong execution, margin improvement, favourable macro and sector re-rating |
| Base Case | Rs 184 | Steady performance, gradual recovery, margins hold, growth on track |
| Bear Case | Rs 156 | Demand deterioration, margin pressure, sector de-rating and macro headwinds |
The bull case Pharmed stock forecast of Rs 192 assumes most positive variables converge. The base case of Rs 184 is the analyst consensus and may or may not be achieved.
How Analysts Are Reading the Pharmed Stock Story
Analyst reviews of the Pharmed share price prediction highlight the company’s core strengths in Pharmaceuticals and Healthcare alongside near-term headwinds from macro uncertainty, competitive pressure and sector-level challenges. Overall the analyst consensus for Pharmed is built on real business strengths set against real risks.
Key Risks to the Pharmed Stock Prediction
USFDA Regulatory Risk
Import alerts and warning letters from the USFDA are the most significant risks to the Pharmed stock prediction. A facility closure would force an immediate sharp revision to the Pharmed share price prediction.
Price Erosion in the US
Pricing pressure in US generics compresses the revenue per product and affects the Pharmed stock forecast. Aggressive price erosion pushes the Pharmed share price prediction toward the bear case.
R&D Execution Risk
Delays in clinical trials or approval failures affect the Pharmed stock prediction. The Pharmed share price prediction is particularly sensitive to key pipeline asset announcements.
Currency Risk
A strengthening rupee against the dollar reduces export realisation and affects the Pharmed stock forecast. Currency risk is embedded in conservative Pharmed share price prediction models.
How to Monitor the Pharmed Stock Forecast
Track the Pharmed share price prediction consensus quarterly. After every earnings release, most brokerages revise their Pharmed stock forecast within two weeks. Comparing the revised analyst target to the previous estimate tells you whether sentiment on Pharmed is improving or deteriorating.
Compare the current price of Rs 160 with the analyst target range of Rs 192 to Rs 175. A wide target band reflects genuine uncertainty on Pharmed, so position size should reflect that range rather than the midpoint alone.
Review the Pharmed share price prediction every quarter against key business metrics for the Pharmaceuticals and Healthcare sector. A single estimate from any analyst is a point-in-time view and should be treated as one input among many when making any investment decision.
Check Live Pharmed Fundamentals on the Univest Screener
Conclusion
The Pharmed stock prediction for 2026 reflects the analyst community’s assessment of Pharmed Ltd’s competitive position, earnings trajectory and macro environment. JM Financial holds a Neutral stance with a target of Rs 192 while Kotak Securities has a Neutral rating with a target of Rs 175, giving an analyst consensus of Rs 184.
The Pharmed stock forecast is set against near-term risks that make the Pharmed share price prediction range wide. Investors should verify any estimate with the latest brokerage reports before using it as an investment reference. The analyst forecast will be revised after every quarterly result, so tracking how the Pharmed share price target changes over time is more valuable than relying on any single estimate.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.
Download the Univest iOS App or Univest Android App to track live analyst targets, price movements and research updates for Pharmed in real time.
Disclaimer: Data and figures in this article are sourced from publicly available information and may or may not be accurate. Analyst price targets are from public brokerage reports and should be independently verified. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Pharmed Stock Prediction 2026
What is the Pharmed stock prediction for 2026?
Ans. The Pharmed stock prediction for 2026 is based on analyst consensus from JM Financial and Kotak Securities. The consensus target is Rs 184. All estimates may or may not be achieved.
Is the Pharmed stock prediction bullish or bearish?
Ans. JM Financial has a Neutral rating with target Rs 192. Kotak Securities has a Neutral rating with target Rs 175. The Pharmed stock forecast reflects genuine analyst diversity of opinion.
What is the Pharmed share price prediction based on fundamentals?
Ans. The Pharmed share price prediction rests on the US generic pipeline, domestic growth, EBITDA margin and regulatory compliance track record. Analysts tracking Pharmed closely cite these as the primary drivers of the 2026 outlook.
What is the long-term Pharmed stock prediction?
Ans. The long-term outlook assumes Pharmed sustains its core business drivers over a multi-year horizon. The 12-month consensus of Rs 184 is the nearest reliable anchor point.
What are the key risks to the Pharmed stock prediction?
Ans. The primary risks include sector-specific headwinds, macro uncertainty, regulatory changes and competitive pressure. Every analyst estimate for Pharmed should be read alongside its risk assumptions.
What does the Pharmed stock forecast say for 2026?
Ans. JM Financial: Neutral target Rs 192. Kotak Securities: Neutral target Rs 175. These Pharmed share price prediction estimates may or may not prove accurate.
Where can I track the latest Pharmed stock prediction?
Ans. Track the latest analyst targets and price movements for Pharmed on the NSE and BSE websites and on the Univest app and screener for live data.
